ScinoPharm Taiwan Full Year 2023 Earnings Beats Expectations - Simply Wall St
| 1789 Stock | TWD 23.35 0.15 0.64% |
Slightly above 62% of ScinoPharm Taiwan's investor base is looking to short. The analysis of current outlook of investing in ScinoPharm Taiwan suggests that many traders are alarmed regarding ScinoPharm Taiwan's prospects. ScinoPharm Taiwan's investing sentiment can be driven by a variety of factors including economic data, ScinoPharm Taiwan's earnings reports, geopolitical events, and overall market trends.
ScinoPharm Taiwan stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of ScinoPharm daily returns and investor perception about the current price of ScinoPharm Taiwan as well as its diversification or hedging effects on your existing portfolios.
ScinoPharm |
ScinoPharm Taiwan Full Year 2023 Earnings Beats Expectations Simply Wall St
Read at news.google.com
 |
ScinoPharm Taiwan Fundamental Analysis
We analyze ScinoPharm Taiwan's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ScinoPharm Taiwan using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ScinoPharm Taiwan based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash And Equivalents
Cash And Equivalents Comparative Analysis
ScinoPharm Taiwan is currently under evaluation in cash and equivalents category among its peers. Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
ScinoPharm Taiwan Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ScinoPharm Taiwan stock to make a market-neutral strategy. Peer analysis of ScinoPharm Taiwan could also be used in its relative valuation, which is a method of valuing ScinoPharm Taiwan by comparing valuation metrics with similar companies.
Peers
ScinoPharm Taiwan Related Equities
| 6697 | Information Technology | 0.11 |
| ||
| 6127 | Leatec Fine | 0.35 |
| ||
| 2412 | Chunghwa Telecom | 0.40 |
| ||
| 1734 | Sinphar Pharmaceutical | 0.80 |
| ||
| 1707 | Grape King | 1.59 |
| ||
| 1733 | Apex Biotechnology | 2.06 |
| ||
| 6209 | Kinko Optical | 2.78 |
| ||
| 2485 | Zinwell | 2.85 |
| ||
| 2497 | E Lead | 2.85 |
|
Additional Tools for ScinoPharm Stock Analysis
When running ScinoPharm Taiwan's price analysis, check to measure ScinoPharm Taiwan's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ScinoPharm Taiwan is operating at the current time. Most of ScinoPharm Taiwan's value examination focuses on studying past and present price action to predict the probability of ScinoPharm Taiwan's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ScinoPharm Taiwan's price. Additionally, you may evaluate how the addition of ScinoPharm Taiwan to your portfolios can decrease your overall portfolio volatility.